KLOW blend

• GHK-Cu50 mg
• BPC-15710 mg
• TB-50010 mg
• KPV10 mg

• Recovery blend courserecommended

  Supplier/community protocol only: 2 mg for 2 weeks, 4 mg for 2 weeks, then 4 mg maintenance. The supplier's optional 6 mg step (week 5+) is not in this plan.

• Supplier protocol (community/supplier practice, not from a label or trial): once daily subcutaneous, 8-12 weeks (extend to 16 if desired).
• Start 7.5 units of the 3 mL mix (= 2 mg of blend), 15 units (4 mg) from week 3, 22.5 units (6 mg) from week 5 as tolerated; the page calls 15 units maintenance.

Route: Subcutaneous, once daily (supplier).

Timing: No reliable figure found in the sources; ask your prescriber or supplier.

• Supplier: add 3.0 mL bacteriostatic water to the 80 mg vial = 26.7 mg/mL blend (about 16.7 mg/mL GHK-Cu and 3.33 mg/mL each of the others). 1 unit (0.01 mL) = 0.267 mg blend.
• Per-vial ingredient amounts 50/10/10/10 mg are derived from the supplier's per-mL figures x 3 mL; the page does not print per-vial mg. Verify on your label.

Supplier: refrigerate at 2-8 C and use within 14-28 days (14 days used here, the conservative end).

Not found in sources.

Why:

• Never draw into the same syringe as another compound; use separate syringes and distinct injection sites. This rule applies to other compounds, not within the premixed blend.

Unapproved. Sold as 'research use only'. FDA placed BPC-157, KPV, the TB-500 fragment and injectable GHK-Cu in Category 2 (significant safety risks) in 2023; by 2026 some were removed or under advisory review: check the FDA list for current status.

No reliable source names a biomarker for this compound.

• Supplier guide: KLOW 80 mg vial dosage protocol (vendor page, research-use-only)
• FDA 503A bulk-substance categories (BPC-157, KPV, TB-500 fragment, GHK-Cu)
• Frier Levitt: FDA 2026 Category 2 update (secondary)